Clinical Trial Update: FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients [Phase 4]

View source ↗

Summary

A Phase 4 trial examining the relationship between FGF-23 and endothelial dysfunction in diabetic patients with proteinuria has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Diabetic Nephropathy

Snippet

Sponsor: Gulhane School of Medicine | Conditions: Proteinuria, Diabetic Nephropathy | Phase 4 | Status: COMPLETED